OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100
https://www.opko.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工: 3,930
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Phillip Frost Ph.D. | Chairman & CEO | 1.45M | 無 | 1936 |
| Dr. Jane H. Hsiao M.B.A., Ph.D. | Vice Chairman & Chief Technical Officer | 1.36M | 無 | 1947 |
| Dr. Elias Adam Zerhouni M.D. | President & Vice Chairman | 1.36M | 無 | 1951 |
| Mr. Adam E. Logal | Senior VP, CFO, Chief Accounting Officer & Treasurer | 1.09M | 無 | 1978 |
| Mr. Steven D. Rubin Esq., J.D. | Executive VP of Administration & Director | 1.22M | 無 | 1960 |
| Dr. Akhtar Ashfaq FACP, FASN, M.D. | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal | 無 | 無 | 無 |
| Dr. Gary J. Nabel M.D., Ph.D. | Chief Innovation Officer & Director | 無 | 無 | 1955 |
| Dr. Charles W. Bishop | Chief Executive Officer of OPKO Renal | 無 | 無 | 1952 |
| Dr. Antonio F. Cruz | President of Transition Therapeutics | 無 | 無 | 1953 |
| Mr. Hans Berner | President of OPKO Health Iberoamerica | 無 | 無 | 無 |
描述
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
公司管治
截至 2024年5月1日 止，OPKO Health, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：10；股東權利：3；現金賠償：7。
